Is Axsome Therapeutics a Screaming Buy?
The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ: AXSM), notching two wins and one failure in late-stage clinical trials.
On March 30, the company reported its drug AXS-05 failed to achieve the primary endpoint in a phase 3 clinical trial for patients with treatment-resistant depression. Weeks later, Axsome hailed a clinical trial success with AXS-05 for Alzheimer's disease-related agitation. In between those two events, the company boasted that another drug, ASX-07, had successfully completed a phase 3 trial for migraine pain.
Image Source: Getty Images.
Source Fool.com
